Sedating a Toddler for an MRI: Chloral Hydrate Is Gone — What Replaces It?
A single patient needing thirty motionless minutes for an MRI. The disagreement isn't nostalgic for chloral hydrate — nobody wants it back — it's about which of its modern replacements actually fits a child with his specific risk profile.
Ronan P. is 20 months old, corrected for the nine weeks he arrived early, and the incidental kidney finding on a recent ultrasound is almost certainly nothing — his pediatrician has said as much twice — but "almost certainly nothing" still needs an MRI to confirm, and an MRI needs thirty uninterrupted minutes of a toddler lying still inside a loud machine, which is not a thing toddlers do voluntarily. A generation ago, this would have been a chloral hydrate sedation, a drug administered to children for imaging and minor procedures for decades before its unpredictable absorption, prolonged and variable sedation depth, and a genuine, documented risk of respiratory depression that outlasted the procedure itself pushed it out of routine pediatric use — it isn't commercially manufactured for this indication in the U.S. any longer, which makes today's actual choice a real one among its modern replacements rather than a choice against the old drug at all.
Ronan's own history narrows that choice more than a routine sedation would. He was born at 31 weeks, and while he has needed no respiratory support since his NICU discharge, a history of prematurity carries a real, if now largely resolved, association with airway reactivity and a lower margin for respiratory depression relative to a term infant of the same current age — former preterm infants are named as a distinct higher-risk group in the AAP/AAPD sedation guideline (Coté and Wilson), which is the document that also drove chloral hydrate out of routine use. Propofol offers the fastest, most predictable onset and offset of the three modern options, which matters for an MRI schedule, but its dose-dependent respiratory depression and lack of analgesic effect on its own make it the option with the narrowest margin in a child whose respiratory reserve, though currently normal on exam, has a history worth respecting. Ketamine preserves airway reflexes and spontaneous respiration better than either alternative, a real advantage in exactly this risk profile, but its own association with increased secretions and a documented, if generally self-limited, emergence-reaction rate makes it an imperfect match for a study requiring true motionlessness rather than sedation alone. Dexmedetomidine produces a more natural sleep-like state with minimal respiratory depression at standard doses, the property most directly relevant to Ronan's history, at the cost of a slower onset and a real risk of bradycardia that needs monitoring rather than being an afterthought.
Sedation planning, morning of the MRI
I'd use dexmedetomidine as the base sedative here. His prematurity history is the one real risk factor his chart actually raises, and dexmedetomidine's minimal respiratory depression at standard doses is the modern option that most directly answers it — the slower onset is a real cost, but this is an elective, unhurried study with no reason to trade safety margin for schedule speed.
If his exam or history suggested any current respiratory concern, I'd be even more confident in this. As it stands, the history alone is enough to tip me here rather than toward propofol.
I'd lean propofol, honestly. His current exam is normal, he's needed no respiratory support in well over a year, and propofol's faster onset and offset mean less total sedation time and a quicker recovery for a family who is here often enough that appointment burden is a real consideration, not an abstract one.
I don't think a resolved history from 20 months ago should carry the same weight as an active clinical finding today would — treating it as though it still fully applies risks over-restricting a child whose actual exam doesn't support that level of caution.
I think you're both reasoning soundly from different weights on the same uncertain variable — how much a resolved prematurity history should still count. Rather than fully committing either way, I'd start with a lower dose of dexmedetomidine as the base, using its respiratory-sparing profile as the actual safety margin, and hold a small propofol bolus in reserve only if he needs additional stillness once the scan starts.
That gets us most of propofol's schedule benefit if he settles well on dexmedetomidine alone, while keeping the more conservative drug as the foundation rather than the rescue.
Dexmedetomidine given as the base sedative; small-dose propofol bolus held in reserve for additional stillness only if needed once scanning begins; standard respiratory and hemodynamic monitoring throughout given the bradycardia risk of dexmedetomidine.
Not agreed, and the reason the plan carries an explicit branch point rather than a single expectation:
This becomes the documented preferred approach for any future imaging sedation, without needing the propofol top-up at all.
The radiologist's throughput concern is partly vindicated, and future planning may shift toward starting with a slightly higher dexmedetomidine dose to reduce the need for a top-up.
How much weight a resolved prematurity history should carry against a normal current exam, more broadly than just today's case — the radiologist's and anesthesiologist's differing defaults on this weren't reconciled, only hedged around for this specific patient.